NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Vir Biotechnology, Inc. (VIR) Stock Analysis

Vir Biotechnology, Inc. (VIR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VIR

$11.39

−$0.06 (−0.57%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VIR with… →

VIR Key Statistics

As of Sep 4, 2026
Trading
Open
$11.31
Previous Close
$11.45
Day's Range
11.18–11.65
52-Week Range
4.75–11.94
Volume
1.15M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.63
Valuation
Market Cap
$1.93B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.35
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.77
Financials (FY)
Revenue (FY)
$66.52M+4.41%
Net Income (FY)
−$437.99M
Profit marginThe share of revenue left as profit after all costs and taxes.
−83.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
169.22M
1-Year Return
+121.50%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.93M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VIR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+88.81%
2025−17.85%
2024−27.04%
2023−60.25%
2022−39.55%
2021+56.35%
2020+112.96%
2019 (partial year)−10.31%

As of September 4, 2026.

VIR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$66.52M−$437.99M−658.4%
2024$63.71M−$521.96M−819.2%
2023$39.49M−$615.06M−1557.4%
2022$1.58B$515.84M32.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$66.52M$66.49M−$479.51M−$437.99M−658.4%
2024$63.71M$62.87M−$552.17M−$521.96M−819.2%
2023$39.49M$36.73M−$670.75M−$615.06M−1557.4%
2022$1.58B$1.43B$833.07M$515.84M32.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VIR Valuation vs Biotechnology Median

Median of 656 stocks
MetricVIRBiotechnology medianvs median
P/S ratio6.3515.2658% below
Profit margin−83.00%0.00%83.0 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Vir Biotechnology, Inc. (VIR) carries a market capitalisation of $1.93B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 367 employees.

The most recent close on file for VIR is $11.39, dated September 4, 2026. That is −$0.06 (−0.57%) against the previous close. The 52-week range on file runs from $4.75 to $11.94. The latest close sits 139.68% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $66.52M. Against the prior fiscal year total of $63.71M, that is a change of +4.41%. The same year closed with a net loss of $437.99M. Profit margin runs at −83%. That is 83 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −1.77.

Across the 4 fiscal years on file, revenue moves from $1.58B in 2022 to $66.52M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 6.35 times revenue. On price-to-sales that is 58.38% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +121.50%. Across 5 years the annualized return works out at −25.30%. Beta against the wider market is reported at 1.63. Annualized volatility over the trailing 6 years is 83.17%.

Growth & Income

No dividend is on file for VIR.

The strongest complete calendar year on file is 2020 at +112.96%; the weakest is 2023 at −60.25%. Of the 6 complete calendar years on file, 2 finished higher. So far in 2026 the price is +88.81%.

Peer Comparison

Vir Biotechnology, Inc. (VIR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Vir Biotechnology, Inc. VIR $1.93B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Vir Biotechnology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Visit website →